Publication:
The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design

dc.contributor.authorJimenez-Sousa, Maria Angeles
dc.contributor.authorGómez-Moreno, Ana Zaida
dc.contributor.authorPineda-Tenor, Daniel
dc.contributor.authorMedrano, Luz Maria
dc.contributor.authorSánchez-Ruano, Juan José
dc.contributor.authorFernandez-Rodriguez, Amanda
dc.contributor.authorArtaza-Varasa, Tomas
dc.contributor.authorSaura-Montalbán, José
dc.contributor.authorVázquez-Morón, Sonia
dc.contributor.authorRyan, Pablo
dc.contributor.authorResino, Salvador
dc.contributor.funderInstituto de Salud Carlos III
dc.date.accessioned2018-12-26T14:26:14Z
dc.date.available2018-12-26T14:26:14Z
dc.date.issued2018-05-09
dc.description.abstractThe polymorphisms at the α-chain of the IL-7 receptor (IL7RA) have been related to T-cell homeostasis and development and may contribute to immune system deregulation. In the present study, we analyzed the association between IL7RA polymorphisms and the progression of liver fibrosis in patients infected with HCV. We carried out a retrospective study with a design consisting of repeated measurements in 187 HCV-infected patients, to study the risk prediction of liver fibrosis progression using genetic factors. We genotyped the rs6897932, rs987106 and rs3194051 IL7RA polymorphisms using the Agena Bioscience's MassARRAY. Transient elastography was used to measure liver stiffness. The used cut-offs were: <7.1 kPa (F0-F1), 7.1-9.4 kPa (F2; significant fibrosis), 9.5-12.4 kPa (F3; advanced fibrosis), and ≥12.5 kPa (F4; cirrhosis). All HCV genotypes were analyzed. The median of follow-up time was 47.9 months. Baseline liver stiffness measurement (LSM) values did not show significant statistical differences for IL7RA genotypes (p>0.05). In univariate analysis, the rs6897932 T allele had a positive relationship with an increase in LSM (arithmetic mean ratio (AMR) = 1.21 (95%CI = 1.08; 1.36); p = 0.001), progression to advanced fibrosis (F≥3) (odds ratio (OR) = 2.51 (95%CI = 1.29; 4.88); p = 0.006) and progression to cirrhosis (F4) (OR = 2.71 (95%CI = 0.94; 5.03); p = 0.069). In multivariable analysis, the rs6897932 T allele was related to a higher increase of LSM values during follow-up (adjusted AMR = 1.27 (95%CI = 1.13; 1.42); p<0.001) and higher odds of progression to advanced fibrosis [adjusted OR = 4.46 (95%CI = 1.87; 10.62); p = 0.001], and progression to cirrhosis [adjusted OR = 3.92 (95%CI = 1.30; 11.77); p = 0.015]. Regarding IL7RA rs987106 and rs3194051 polymorphisms, we did not find significant results except for the relationship between IL7RA rs987106 and the increase in LSM values [adjusted OR = 1.12 (95%CI = 1.02; 1.23); p = 0.015]. The IL7RA rs6897932 polymorphism seems to be related to increased risk of liver fibrosis progression in HCV-infected patients. Thus, the rs6897932 polymorphism could be related to the physiopathology of CHC and might be used to successfully stratify the risk of CHC progression.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis work has been supported by grants given by Fondo de Investigación de Sanidad en España (FIS) [Spanish Health Founds for Research] [grant numbers PI14CIII/00011, PI15CIII/00024 and PT13/0001]. MAJS, LMM, and AFR are supported by “Instituto de Salud Carlos III” [grant numbers CD13/00013, CD14/00002 and CP14/0010].es_ES
dc.format.number5es_ES
dc.format.pagee0197115es_ES
dc.format.volume13es_ES
dc.identifier.citationPLoS One. 2018 May 9;13(5):e0197115.es_ES
dc.identifier.doi10.1371/journal.pone.0197115es_ES
dc.identifier.e-issn1932-6203es_ES
dc.identifier.issn1932-6203es_ES
dc.identifier.journalPloS onees_ES
dc.identifier.pubmedID29742149es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6942
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS)
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14CIII/00011es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI15CIII/00024es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PT13/0001es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0197115es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdultes_ES
dc.subject.meshDisease Progressiones_ES
dc.subject.meshFemalees_ES
dc.subject.meshGenetic Association Studieses_ES
dc.subject.meshGenotypees_ES
dc.subject.meshHepaciviruses_ES
dc.subject.meshHepatitis C, Chronices_ES
dc.subject.meshHumanses_ES
dc.subject.meshInterleukin-7 Receptor alpha Subunites_ES
dc.subject.meshLiveres_ES
dc.subject.meshLiver Cirrhosises_ES
dc.subject.meshMalees_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshPolymorphism, Single Nucleotidees_ES
dc.subject.meshGenetic Predisposition to Diseasees_ES
dc.titleThe IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements designes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication2bf7faec-7f00-44ba-9494-efb396305551
relation.isAuthorOfPublication4714ae6f-ef4b-41fa-bcd0-38b37f0ae2a3
relation.isAuthorOfPublication358a1c6d-3f44-4ee0-b523-dedc5a675f6b
relation.isAuthorOfPublication6a32a4a3-2d81-43c5-8295-48346efbf498
relation.isAuthorOfPublication67f2bc43-2edd-4446-a434-c8145a43f451
relation.isAuthorOfPublication89b17350-14e3-4dfd-b797-6ee6ca5363b8
relation.isAuthorOfPublication.latestForDiscovery2bf7faec-7f00-44ba-9494-efb396305551
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublicationa2759e3d-0d58-4e8a-9fcd-c6130ee333d1
relation.isPublisherOfPublication.latestForDiscoverya2759e3d-0d58-4e8a-9fcd-c6130ee333d1

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
TheIL7RArs6897932Polymorphism_2018.pdf
Size:
2.44 MB
Format:
Adobe Portable Document Format
Description: